Somatrogon vs Somatropin: How Once-Weekly and Daily Growth Hormone Compare

Somatrogon and somatropin are both prescription forms of recombinant human growth hormone, and the biggest difference is how often they are injected. Somatrogon (brand name Ngenla) is a long-acting growth hormone analog given once a week, while somatropin (sold as Humatrope, Genotropin, Norditropin, Omnitrope, and others) is given once a day. Both are FDA-approved for growth hormone deficiency in children, but somatropin is approved for many more conditions and has decades of real-world safety data behind it.

Somatrogon vs Somatropin at a Glance

Feature	Somatrogon (Ngenla)	Somatropin (Humatrope, Genotropin, etc.)
Molecule	Long-acting analog: human growth hormone fused to a C-terminal peptide	Recombinant human growth hormone, 191 amino acids, identical to native hGH
Injection schedule	Once weekly	Once daily
First U.S. approval	June 2023	Mid-1980s
FDA-approved uses	Pediatric growth hormone deficiency, ages 3 and older	Pediatric and adult GHD, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, small for gestational age, idiopathic short stature, HIV wasting, and others
Adult use	Not approved	Approved for adult growth hormone deficiency
Typical pediatric dose	0.66 mg/kg once weekly	About 0.16 to 0.24 mg/kg per week, split into daily doses
Routine monitoring	IGF-1, growth velocity, anti-drug antibodies	IGF-1, growth velocity, thyroid function, glucose

How the Two Molecules Differ

Somatropin is the simpler of the two. It is a 191-amino-acid protein that matches the growth hormone your pituitary gland produces. Products described as 191 amino acid HGH are chemically the same molecule, which is why hgh 191aa vs somatropin comparisons usually end in a draw.

Somatrogon takes that same protein and attaches a short piece of the human chorionic gonadotropin beta chain. That addition slows clearance from the body and stretches the dosing interval from one day to one week.

Somatrogon is not interchangeable with somatropin on a milligram-for-milligram basis. The fusion changes how long the drug stays active, so a weekly somatrogon dose looks much larger than a single daily somatropin dose even though both are titrated to the same IGF-1 target.

Dosing: 52 Injections a Year vs. 365

Daily somatropin means roughly 365 subcutaneous injections a year for a child. Weekly somatrogon means 52. That difference is the main reason the weekly option exists.

Adherence matters in growth hormone therapy. Missed daily doses are common, and children who miss doses grow less than children who receive the full regimen. A once-weekly injection removes most of that day-to-day burden for families.

The trade-off is flexibility and injection volume. Daily dosing lets a clinician fine-tune the amount and react quickly when IGF-1 levels drift, while a weekly injection delivers a larger volume at a single site and leaves a longer gap if a dose is skipped.

Approved Uses: Where the Labels Diverge

Somatrogon is approved only for pediatric growth hormone deficiency in children 3 years and older. Somatropin carries a much broader label that includes adult growth hormone deficiency, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, children born small for gestational age, idiopathic short stature, and HIV-associated wasting.

Somatrogon is not FDA-approved for adults or for any condition other than pediatric growth hormone deficiency.

Brand-level questions such as omnitrope vs somatropin are mostly about delivery device, concentration, and price, because the active ingredient is the same recombinant hormone. The same logic applies to serostim vs somatropin: Serostim is simply a somatropin product approved for HIV-related wasting, not a different drug.

Neither somatrogon nor somatropin is FDA-approved for anti-aging, weight loss, or athletic performance.

Effectiveness: What the Head-to-Head Trial Found

In a 12-month phase 3 trial in prepubertal children with growth hormone deficiency, once-weekly somatrogon was non-inferior to daily somatropin. Annualized height velocity was about 10.1 cm per year with somatrogon and 9.8 cm per year with somatropin.

IGF-1 responses and overall safety findings were broadly similar between the two treatment groups.

The real gap is duration of evidence. Somatropin has been studied for decades, including trials that follow children all the way to final adult height. Somatrogon was approved on the basis of 12-month height velocity data rather than final adult height outcomes. Long-term growth results for the weekly product are still being collected.

Side Effects and Monitoring

Both drugs share the same class effects. Common issues include injection site reactions, headache, and shifts in thyroid or blood sugar levels. Rare but serious risks include intracranial hypertension, slipped capital femoral epiphysis, and fluid retention.

Somatrogon adds one consideration: anti-drug antibodies. A notable share of children in the clinical program developed antibodies against somatrogon, and higher antibody titers were sometimes associated with a smaller growth response.

Routine monitoring for either drug includes IGF-1 levels, growth velocity, thyroid function, and glucose. Both are contraindicated in active cancer, active diabetic retinopathy, and children whose growth plates have already closed.

Anyone considering growth hormone therapy should work with a pediatric endocrinologist or endocrinologist rather than self-directing treatment, and should discuss risks, benefits, and alternatives before starting.

Cost, Access, and Alternatives People Ask About

Both products are expensive, often tens of thousands of dollars per year before insurance. Coverage depends on the diagnosis, prior authorization requirements, and the plan's preferred product list.

Other options are frequently compared online, though most work differently. Somatropin vs sermorelin debates contrast a finished hormone with a peptide that prompts the pituitary to release more of its own growth hormone, and hgh fragment 176-191 vs somatropin comparisons involve a truncated peptide fragment that is not growth hormone at all.

Unapproved injectable products sold online are a separate category entirely, with no guarantee of purity, potency, or sterility.

Key Takeaways

• Somatrogon is a once-weekly, long-acting growth hormone analog, while somatropin is a daily recombinant human growth hormone.
• Somatrogon is FDA-approved only for pediatric growth hormone deficiency in children 3 years and older.
• Somatropin is FDA-approved for a much wider list of conditions, including adult growth hormone deficiency.
• Once-weekly somatrogon matched daily somatropin on 12-month height velocity in a phase 3 trial.
• Neither product is approved for anti-aging, weight loss, or sports performance.

COMMON QUESTIONS

Frequently Asked Questions

Is somatrogon the same as somatropin?

No. Somatrogon is a long-acting growth hormone analog injected once a week, while somatropin is recombinant human growth hormone identical to the body's own hormone and is injected daily. They are not interchangeable at the same milligram dose because the fusion in somatrogon changes how long the drug stays active.

Is once-weekly somatrogon as effective as daily somatropin?

In a 12-month phase 3 trial in prepubertal children with growth hormone deficiency, once-weekly somatrogon produced height velocity that was non-inferior to daily somatropin, about 10.1 cm versus 9.8 cm per year. Long-term data on final adult height are still more limited for somatrogon than for somatropin.

Can adults use somatrogon for growth hormone deficiency?

No. Somatrogon (Ngenla) is FDA-approved only for children 3 years and older with growth hormone deficiency. Adults with growth hormone deficiency are typically treated with daily somatropin products under the supervision of an endocrinologist.